MétaCan
Menu
Back to cohort
Record W4409148188 · doi:10.1016/j.euf.2025.03.011

Metastasis-directed Therapy in the Management of Urothelial Carcinoma: A Systematic Review and Meta-analysis

2025· review· en· W4409148188 on OpenAlexaff
Marcin Miszczyk, Mateusz Bilski, Tamás Kói, Katarzyna Konat-Bąska, Agata Suleja, Tamás Fazekas, Akihiro Matsukawa, Ichiro Tsuboi, R. J. Schulz, Paweł Rajwa, Ekaterina Laukhtina, Melanie R. Hassler, Giulia Marvaso, Paul Sargos, Piet Ost, Guillaume Ploussard, Barbara Alicja Jereczek‐Fossa, Morgan Rouprêt, Piotr Chłosta, Pierre I. Karakiewicz, Marek Babjuk, Jeremy Yuen‐Chun Teoh, Marco Moschini, Paolo Gontero, Shahrokh F Shariat

Bibliographic record

VenueEuropean Urology Focus · 2025
Typereview
Languageen
FieldMedicine
TopicBladder and Urothelial Cancer Treatments
Canadian institutionsUniversité de Montréal
FundersMSD AustraliaMeso Scale DiagnosticsAgencja Badań MedycznychNarodowa Agencja Wymiany AkademickiejBayer
KeywordsMedicineMetastasectomyMeta-analysisConfidence intervalInternal medicineOncologyMetastasisLung cancerCancerSurgery

Abstract

fetched live from OpenAlex

BACKGROUND AND OBJECTIVE: In this prospectively registered meta-analysis (PROSPERO: CRD42024501283), we pooled data on patients treated with metastasis-directed therapies (MDTs) for metastatic urothelial cancer (mUC). METHODS: On January 24, 2024, we searched PubMed (MEDLINE), Scopus, and Google Scholar for studies on consolidative MDT in patients with mUC. The search was updated on August 25, 2024. Reports of MDT for brain metastases were excluded. The survival data were synthesised with a distribution-free approach using individual patient data extracted from Kaplan-Meier plots. The risk of bias was assessed using the Risk Of Bias In Non-randomised Studies of Interventions (ROBINS-I) tool. KEY FINDINGS AND LIMITATIONS: We included 19 retrospective and one prospective study, encompassing a total of 616 patients, published between 2003 and 2024. The median age ranged between 56 and 72 yr. Most patients were treated with surgical metastasectomy (73%), and approximately half received MDT as a first line of treatment for metastases. The pooled 2- and 5-yr overall survival (OS) rates were 64% (95% confidence interval [CI] 58-71%) and 38% (95% CI 33-45%). The median OS was 46.2 mo in patients treated for lung metastases (95% CI 28.7-62.6), 31.2 mo in those treated for lymph node metastases (95% CI 16.1-51.8), and 29 mo in those with mixed-location metastases (95% CI 23.8-38.4). The main limitations were heterogeneity, lack of data from comparative studies, and low quality of the evidence. CONCLUSIONS AND CLINICAL IMPLICATIONS: Many patients with mUC selected for MDT achieve long-term survival, particularly those with lung metastases. Although a causal association cannot be established, MDT emerges as a promising research direction, especially in combination with novel systemic therapies capable of eliciting deep, sustained responses.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.020
metaresearch head score (Gemma)0.036
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.020
Threshold uncertainty score0.104

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0200.036
Meta-epidemiology (narrow)0.0030.001
Meta-epidemiology (broad)0.0180.040
Bibliometrics0.0080.008
Science and technology studies0.0010.001
Scholarly communication0.0030.002
Open science0.0020.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.072
GPT teacher head0.342
Teacher spread0.270 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations7
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Urology FocusSame topicBladder and Urothelial Cancer TreatmentsFrench-language works237,207